搜尋
Urogen Pharma Ltd
URGN添加自選
37.940USD
+1.140+3.10%
收盤 07/01, 16:00（美東）報價延遲15分鐘
1.85B總市值
虧損本益比TTM
關於 Urogen Pharma Ltd 公司
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd簡介
公司代碼URGN
公司名稱Urogen Pharma Ltd
上市日期May 04, 2017
CEOBarrett (Elizabeth A)
員工數量235
證券類型Ordinary Share
年結日May 04
公司地址9 Ha'ta'asiya St
城市RA'ANANA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編4365007
電話97297707601
網址https://www.urogen.com/
公司代碼URGN
上市日期May 04, 2017
CEOBarrett (Elizabeth A)
Urogen Pharma Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
常見問題
Urogen Pharma Ltd的前五大股東是誰？
Urogen Pharma Ltd的前五大股東如下：Dr. Arie S. Belldegrun, M.D.
有多少機構持有Urogen Pharma Ltd(URGN)的股份？
截至2026Q1，共有349家機構持有Urogen Pharma Ltd的股份，合計持有的股份價值約為46.29M，占公司總股份的95.00% 。與2025Q4相比，機構持股有所增加，增幅為-15691017.00。
哪個業務部門對Urogen Pharma Ltd的收入貢獻最大？
在2026Q1，Jelmyto業務部門對Urogen Pharma Ltd的收入貢獻最大，創收93.99M，占總收入的85.61% 。